上機數控(603185.SH):與新疆協鑫簽訂50.84億元多晶硅料長單採購合同
格隆匯5月18日丨上機數控(603185.SH)公佈,公司於2019年拓展單晶硅業務,產能持續擴大,在生產過程中對原材料的需求也逐步增加。同時,公司新增的10GW的單晶硅產能正在建設中。為充分保障原材料的供應,公司下屬全資子公司弘元新材與新疆協鑫新能源材料科技有限公司(簡稱“新疆協鑫”)就“多晶硅料”的採購簽訂合同,預計2021年6月至2023年12月採購數量為3.1萬噸。
參照PVInfoLink最新公佈的價格測算,預計合同金額約為2021-2023年50.84億元(含税),不含税為44.99億元。該金額僅為根據當前市場價格測算,實際以簽訂的月度補充協議為準。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.